Latest Cardiac marker Stories
ANAHEIM, Calif., Sept.
The global medical biomarker market is valued at about $25.9 billion for 2013, an increase of 10.2% since last year.
A simple blood test can help identify people who are at high risk of dying within the month after non-cardiac surgery.
BERLIN, May 18, 2011 /PRNewswire/ -- Research presented this week at the International Federation of Clinical Chemistry Congress and Laboratory Medicine showed that using a lower diagnostic threshold for troponin improves clinical outcomes and patient survival in patients with suspected acute coronary syndromes.
Novel research illustrates that elevated levels of cardiac troponin T (cTnT) or I (cTnI) in patients who had angioplasty indicate a higher risk of all-cause mortality in addition to long-term harmful events such as heart attack.
New research shows that elevated levels of cardiac troponin T (cTnT) or I (cTnI) in patients who had angioplasty indicate a higher risk of all-cause mortality and long-term adverse events such as heart attack.
Patients who underwent coronary artery bypass graft surgery and had elevated levels of the cardiac enzymes creatine kinase or troponin in the 24 hours following surgery had an associated intermediate and long-term increased risk of death.
Researchers at Mount Sinai School of Medicine have found that even small amounts of damage to heart muscle during coronary artery bypass grafting (CABG) is associated with an increased risk of death, even among patients who initially do well following surgery.
- totally perplexed and mixed up.